RayKnowChina Research Map
Shortlist0

HefeiAnhui Medical University

First Affiliated Hospital of Anhui Medical University

安徽医科大学第一附属医院

Listed for 28 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at First Affiliated Hospital of Anhui Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌23 papers led
  3. Hepatocellular carcinoma肝细胞癌101 papers led
  4. Stomach cancer胃癌84 papers led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Osteosarcoma骨肉瘤13 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  8. Neuroblastoma神经母细胞瘤1 paper led
  9. Ewing sarcoma尤文肉瘤1 paper led
  10. Multiple myeloma多发性骨髓瘤10 papers led
  11. Aplastic anaemia再生障碍性贫血1 paper led
  12. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜2 papers led
  13. Fanconi anaemia范可尼贫血1 paper led
  14. Myasthenia gravis重症肌无力4 papers led
  15. Wilson disease肝豆状核变性(Wilson 病)1 paper led
  16. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎7 papers led
  17. Takayasu arteritis大动脉炎2 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
  19. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  20. IgA nephropathyIgA 肾病11 papers led
  21. Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
  22. Primary biliary cholangitis原发性胆汁性胆管炎3 papers led
  23. Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
  24. Congenital diaphragmatic hernia先天性膈疝0 papers led
  25. Hirschsprung disease先天性巨结肠1 paper led
  26. Inherited epidermolysis bullosa遗传性大疱性表皮松解症2 papers led
  27. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
  28. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Hepatoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Osteogenesis imperfecta, Hereditary angioedema, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

2 hospitals in Hefei for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AISide effects & quality of life
Departments in papersENT / head & neck surgeryRadiology / nuclear medicineRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 23 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
23
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 4420232024: 4420242025: 11112025

4 hospitals in Hefei for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07787273

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AISurgeryMolecular markers & genomics
Departments in papersRadiation oncologyMedical oncology
Papers it led23
  1. CT-Based Deep Learning Predicts Prognosis in Esophageal Squamous Cell Cancer Patients Receiving Immunotherapy Combined with Chemotherapy.2025Academic radiology
  2. Correlative analysis of immune-related thyroid dysfunction and prognosis in patients with advanced esophageal squamous cell carcinoma.2025Anti-cancer drugs
  3. Radical surgery versus definitive radiotherapy in treatment of locoregional upper esophageal squamous cell carcinoma.2025BMC cancerFree full text
  4. Prognostic value of serum inflammatory markers in patients with esophageal squamous cell carcinoma undergoing surgery: a two-center retrospective cohort study.2025BMC cancerFree full text
  5. EZH2 suppresses IR-induced ferroptosis by forming a co-repressor complex with HIF-1α to inhibit ACSL4: Targeting EZH2 enhances radiosensitivity in KDM6A-deficient esophageal squamous carcinoma.2025Cell death and differentiationFree full text
  6. Radiomics and prognostic nutritional index for predicting postoperative survival in esophageal carcinoma.2025European journal of medical researchFree full text
  7. SNRPB2 facilitates esophageal squamous cell carcinoma oncogenesis and progression via E2F4 stabilization.2025Frontiers in immunologyFree full text
  8. Multi-Omics Analysis of Aberrances and Functional Implications of IRF5 in Digestive Tract Tumours.2025Journal of cellular and molecular medicineFree full text
  9. Patterns of Lymph Node Recurrence after Esophagectomy of pT2-3 N0M0 Esophageal Squamous Cell Carcinoma.2025Journal of gastrointestinal cancerFree full text
  10. Cervical Incision-Free Technique for R0 Resection in Cervicothoracic Esophageal Carcinoma: A Novel Approach of the Chai's Supra-Thoracic Apex Technique.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. Cancer-associated fibroblasts derived-exosomal circ_0076535 promotes esophageal squamous cell carcinoma progression.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  12. Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus Chemotherapy.2024Annali italiani di chirurgia
  13. Risk factors for postoperative recurrence of pT2-3N0M0 esophageal squamous cell carcinoma and patterns of its recurrence.2024Bioscience trends
  14. Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer.2024Cancer medicineFree full text
  15. Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study.2024The Kaohsiung journal of medical sciencesFree full text
  16. Acacetin restrains the malignancy of esophageal squamous carcinoma cells via regulating JAK2/STAT3 pathway.2023Chemical biology & drug design
  17. Circ_0008726 promotes malignant progression of ESCC cells through miR-206/HOXA13 pathway.2023General thoracic and cardiovascular surgery
  18. Prognostic analysis of radiotherapy for cervical lymph node recurrence after curative resection of thoracic esophageal squamous cell carcinoma.2023Journal of radiation researchFree full text
  19. Prognostic nomogram and risk factors for predicting survival in patients with pT2N0M0 esophageal squamous carcinoma.2023Scientific reportsFree full text
  20. Esophageal stenosis as an independent factor of poor prognosis in patients with ESCC treated with definitive chemoradiotherapy.2022Future oncology (London, England)
  21. LncRNA PTPRG-AS1 facilitates glycolysis and stemness properties of esophageal squamous cell carcinoma cells through miR-599/PDK1 axis.2022Journal of gastroenterology and hepatology
  22. GFI1 promotes the proliferation and migration of esophageal squamous cell carcinoma cells through the inhibition of SOCS1 expression.2021International journal of molecular medicineFree full text
  23. Effect of TRPM2-Mediated Calcium Signaling on Cell Proliferation and Apoptosis in Esophageal Squamous Cell Carcinoma.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status6
  1. Lymph Node Metastasis in Early Esophageal Squamous Cell CarcinomaStatus unknownNCT07050576Lead sponsorStart 2024-05
  2. Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentStatus unknownNCT03224221Lead sponsorPhase 2Start 2017-03
  3. Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07787273Study sitePhase 2Start 2026-03
  4. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  5. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  6. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
More papers found outside PubMed (not counted)23
  1. 2145P Neoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: Primary efficacy/safety results and exploratory single-cell RNA sequencing correlates from a multicenter, prospect2025Annals of Oncologyarticle
  2. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncologyconference-abstract
  3. Real-world effectiveness and safety of first-line serplulimab in patients with metastatic or locally advanced esophageal carcinoma.2025Journal of Clinical Oncologyarticle
  4. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncologyarticle
  5. YWHAZ-Mediated Modulation of Tumor Differentiation Impact on the Long-Term Prognosis in Esophageal Squamous Cell Carcinoma Patients Following Chemoradiotherapy2025Research Squarepreprint
  6. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncologyarticle
  7. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  8. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  9. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  10. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  11. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  12. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  13. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  14. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  15. Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospec2023Journal of Clinical Oncologyconference-abstract
  16. The role of PMI in evaluating the efficacy of PD-1 inhibitors and prognosis of patients treated for advanced esophageal squamous cell carcinoma2023Research Squarepreprint
  17. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  18. DNMT3A promotes the proliferation and metastasis of esophageal squamous cell carcinoma via upregulating HDAC92022Research Squarepreprint
  19. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset
  20. A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results.2021Journal of Clinical Oncologyconference-abstract
  21. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  22. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  23. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 101 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
101
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 171720212022: 141420222023: 151520232024: 252520242025: 28282025

3 hospitals in Hefei for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  2. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  3. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  4. Not yet recruiting
    NK521 in the Treatment of Advanced Solid Tumors
    Phase
    Early phase 1
    Started
    2027-01
    Registry
    NCT07657416

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led101
  1. COA6 deficiency inhibits hepatocellular carcinoma progression by regulating cuproptosis through the JAK/STAT signaling pathway.2026Biochimica et biophysica acta. Molecular cell research
  2. Genetically engineered pig-to-human liver xenotransplantation.2026Journal of hepatology
  3. Nuclear Overexpression of SAMHD1 Induces M Phase Stalling in Hepatoma Cells and Suppresses HCC Progression by Interacting with the Cohesin Complex.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. NSUN5 Facilitates Hepatocellular Carcinoma Progression by Increasing SMAD3 Expression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Causal role of immune cells in primary liver cancer: a mendelian randomization study.2025BMC cancerFree full text
  6. Endoplasmic reticulum stress-related CLIP4 plays a procarcinogenic role in hepatocellular carcinoma: an integrated analysis.2025BMC cancerFree full text
  7. Synthesis and biological evaluation of 68Ga-DOTA-AngII as a radiotracer for PET/MR imaging of hepatocellular carcinoma.2025Bioorganic & medicinal chemistry
  8. Efficacy and Safety of Microwave Ablation in Patients With Hepatocellular Carcinoma With Decompensated Liver Cirrhosis: A Retrospective Study.2025Canadian journal of gastroenterology & hepatologyFree full text
  9. RNF2 induces myeloid-derived suppressor cells chemotaxis and promotes hepatocellular carcinoma progression through the TRAF2-NF-κB signaling axis.2025Cancer immunology, immunotherapy : CIIFree full text
  10. Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.2025Cancer scienceFree full text
  11. Endoplasmic reticulum stress-related super enhancer promotes epithelial-mesenchymal transformation in hepatocellular carcinoma through CREB5 mediated activation of TNC.2025Cell death & diseaseFree full text
  12. Targeting NAT10 attenuates homologous recombination via destabilizing DNA:RNA hybrids and overcomes PARP inhibitor resistance in cancers.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  13. Multi-modality model predicts lung metastasis of hepatocellular carcinoma using MRI and pathological: a retrospective multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  14. A real-world drug safety surveillance study of lenvatinib from the FAERS database.2025Expert opinion on drug safety
  15. NPC1 promotes the progression of hepatocellular carcinoma by mediating the accumulation of neutrophils into the tumor microenvironment.2025FEBS open bioFree full text
  16. The immunomodulatory role of the MAFB gene in hepatocellular carcinoma and its impact on biological activities.2025Gene
  17. Chemokines and PI3K/AKT signaling pathway mediate the spontaneously ruptured hepatocellular carcinoma through the regulation of the cell cycle.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  18. NME2 modulates HCC progression through 4EBP1 phosphorylation and autophagy regulation independent of mTOR.2025Hepatology communicationsFree full text
  19. Exosomes Derived from Endoplasmic Reticulum Stressed Hepatocellular Carcinoma Cells Enhance the Antitumor Immunity of Dendritic Cells.2025Inflammation
  20. Antitumor Effects of Tumor-Derived Exosomes in Murine Hepatocellular Carcinoma Models.2025Iranian journal of immunology : IJI
  21. Acid Sensor Acid-Sensing Ion Channel 1a Promotes Malignant Cell Proliferation Through the Transcription Factor 7/c-Myc Pathway in Liver Cancer.2025Laboratory investigation; a journal of technical methods and pathology
  22. Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study.2025MedicineFree full text
  23. NLR Risk Score for Predicting Patient Prognosis in Hepatocellular Carcinoma and Identification of Oncogenic Role of NLRP5 in Hepatocellular Carcinoma.2025Oncology researchFree full text
  24. Novel Stemness-Associated Scores: Enhancing Predictions of Hepatocellular Carcinoma Prognosis and Tumor Immune Microenvironment.2025Oncology researchFree full text
  25. Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer.2025Pathogens (Basel, Switzerland)Free full text
  26. LARP3 inhibits the apoptosis of hepatocellular carcinoma via the ROS/PI3K/c-Fos axis.2025PloS oneFree full text
  27. The prognostic value and functional role of CPSF3 in hepatocellular carcinoma.2025Scientific reportsFree full text
  28. SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma.2025Scientific reportsFree full text
  29. IL35 modulates HBV-related HCC progression via IL6-STAT3 signaling.2025Scientific reportsFree full text
  30. Efficacy of Perioperative Application of Enhanced Recovery After Surgery on Elderly Recipients Underwent Liver Transplantation.2025World journal of surgery
  31. Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.2024Abdominal radiology (New York)
  32. Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies-Development and Validation of the ABPS Score.2024Academic radiology
  33. Upregulation of multiple key molecules is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma by bulk and single-cell RNA-seq.2024AgingFree full text
  34. Gene variation profile and the potential correlation with clinical characteristics in HBV-associated HCC.2024Asian journal of surgery
  35. Comprehensive Analysis of TICRR in Hepatocellular Carcinoma Based on Bioinformatics Analysis.2024Biochemical geneticsFree full text
  36. SEC24C suppresses the propagation and chemoresistance of hepatocellular carcinoma by promoting unfolded protein response-related apoptosis.2024Bioscience trends
  37. Preoperative Serum Glycan Levels Reflect Progression of Patients With Hepatocellular Carcinoma.2024Cancer medicineFree full text
  38. Prognostic and immune roles of UROC1 in human cancers: from mechanism exploration of NAFLD and HCC to pan-cancer analysis.2024European review for medical and pharmacological sciences
  39. Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway.2024International immunopharmacology
  40. Current Progress of Ferroptosis Study in Hepatocellular Carcinoma.2024International journal of biological sciencesFree full text
  41. Function of microRNA‑124 in the pathogenesis of cancer (Review).2024International journal of oncologyFree full text
  42. Inhibition of UBA52 induces autophagy via EMC6 to suppress hepatocellular carcinoma tumorigenesis and progression.2024Journal of cellular and molecular medicineFree full text
  43. Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma.2024Journal of experimental & clinical cancer research : CRFree full text
  44. Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.2024Journal of nanobiotechnologyFree full text
  45. Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma.2024Journal of translational medicineFree full text
  46. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.2024La Radiologia medica
  47. Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study.2024MedicineFree full text
  48. Ribosomal protein S6 kinase 2 (RPS6KB2) is a potential immunotherapeutic target for cancer that upregulates proinflammatory cytokines.2024Molecular biology reports
  49. Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma.2024Molecular cancerFree full text
  50. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation.2024Oncogene
  51. TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.2024OncogeneFree full text
  52. Causal effect of porphyria biomarkers on alcohol-related hepatocellular carcinoma through Mendelian Randomization.2024PloS oneFree full text
  53. A pan-cancer analysis uncovering the function of CRHBP in tumor immunity, prognosis and drug response: especially its function in LIHC.2024Scientific reportsFree full text
  54. Based on Gadolinium Ethoxybenzyl DTPA-Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma.2024Technology in cancer research & treatmentFree full text
  55. Interactive model for predicting the oncological outcome of patients with early-stage huge hepatocellular carcinoma after hepatectomy: a multicenter population-based study.2024Updates in surgery
  56. Contrast-Enhanced Ultrasound with Deep Learning with Attention Mechanisms for Predicting Microvascular Invasion in Single Hepatocellular Carcinoma.2023Academic radiology
  57. Combining WGCNA and machine learning to construct immune-related EMT patterns to predict HCC prognosis and immune microenvironment.2023AgingFree full text
  58. Circular RNA circ_0003028 regulates cell development through modulating miR-498/ornithine decarboxylase 1 axis in hepatocellular carcinoma.2023Anti-cancer drugs
  59. Cellular senescence-related genes: predicting prognosis in hepatocellular carcinoma.2023BMC cancerFree full text
  60. Oncological prognosis and morbidity of hepatectomy in elderly patients with hepatocellular carcinoma: a propensity score matching and multicentre study.2023BMC surgeryFree full text
  61. COL15A1 interacts with P4HB to regulate the growth and malignancy of HepG2.2.15 cells.2023Biochemical and biophysical research communications
  62. miR-210 promotes hepatocellular carcinoma progression by modulating macrophage autophagy through PI3K/AKT/mTOR signaling.2023Biochemical and biophysical research communicationsFree full text
  63. Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma.2023Cancer medicineFree full text
  64. H2AFX might be a prognostic biomarker for hepatocellular carcinoma.2023Cancer reports (Hoboken, N.J.)Free full text
  65. miR-29c Suppresses the Malignant Phenotype of Hepatocellular Carcinoma Cells In Vitro by Mediating TPX2 Associated with Immune Infiltration.2023Digestive diseases and sciences
  66. Let-7c-5p down-regulates immune-related CDCA8 to inhibit hepatocellular carcinoma.2023Functional & integrative genomics
  67. Experimental models of fatty liver diseases: Status and appraisal.2023Hepatology communicationsFree full text
  68. Association between HMGA1 and immunosuppression in hepatocellular carcinoma: A comprehensive bioinformatics analysis.2023MedicineFree full text
  69. Liquid Biopsy in Hepatocellular Carcinoma.2023Methods in molecular biology (Clifton, N.J.)
  70. Camrelizumab combined with apatinib in the treatment of patients with hepatocellular carcinoma: a real-world assessment.2023Neoplasma
  71. Comprehensive analysis of the expression and prognosis for IQ motif-containing GTPase-activating proteins in hepatocellular carcinoma.2022BMC cancerFree full text
  72. HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression.2022Biochemical and biophysical research communications
  73. Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis.2022BioengineeredFree full text
  74. Circular RNA hsa_circ_0006091 as a novel biomarker for hepatocellular carcinoma.2022BioengineeredFree full text
  75. ARHGEF2/EDN1 pathway participates in ER stress-related drug resistance of hepatocellular carcinoma by promoting angiogenesis and malignant proliferation.2022Cell death & diseaseFree full text
  76. CAF-Released Exosomal miR-20a-5p Facilitates HCC Progression via the LIMA1-Mediated β-Catenin Pathway.2022CellsFree full text
  77. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.2022Clinics and research in hepatology and gastroenterology
  78. Gene Signature and Prognostic Value of Ubiquitin-Specific Proteases Members in Hepatocellular Carcinoma and Explored the Immunological Role of USP36.2022Frontiers in bioscience (Landmark edition)
  79. A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors.2022Frontiers in immunologyFree full text
  80. SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis.2022International journal of biological sciencesFree full text
  81. Development and validation of safety and efficacy-associated risk calculator for hepatocellular carcinoma in the elderly after resection (SEARCHER): A multi-institutional observational study.2022International journal of surgery (London, England)
  82. Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  83. Hemoglobin/Red Blood Cell Distribution Width Ratio in Peripheral Blood Is Positively Associated with Prognosis of Patients with Primary Hepatocellular Carcinoma.2022Medical science monitor : international medical journal of experimental and clinical researchFree full text
  84. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis.2022Oxidative medicine and cellular longevityFree full text
  85. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma.2021Anti-cancer drugsFree full text
  86. Systematic review of outcomes and meta-analysis of risk factors for prognosis after liver resection for hepatocellular carcinoma without cirrhosis.2021Asian journal of surgery
  87. Prognostic value of inflammation-based indices in patients with resected hepatocellular carcinoma.2021BMC cancerFree full text
  88. Development and Validation of an Autophagy-Related Gene Signature for Predicting the Prognosis of Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  89. Immune implication of FAM83D gene in hepatocellular carcinoma.2021BioengineeredFree full text
  90. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma.2021BioengineeredFree full text
  91. The mechanisms of renin-angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  92. Association between socioeconomic status and survival in patients with hepatocellular carcinoma.2021Cancer medicineFree full text
  93. Two novel online nomograms for predicting the survival of individual patients undergoing partial hepatectomy for huge hepatocellular carcinoma.2021HPB : the official journal of the International Hepato Pancreato Biliary Association
  94. Histone deacetylase‑2: A potential regulator and therapeutic target in liver disease (Review).2021International journal of molecular medicineFree full text
  95. PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma.2021OncoimmunologyFree full text
  96. BACH1 is transcriptionally inhibited by TET1 in hepatocellular carcinoma in a microRNA-34a-dependent manner to regulate autophagy and inflammation.2021Pharmacological research
  97. Screening, clinical features and prognostic analysis of liver cirrhosis-related hepatocellular carcinoma.2021Scandinavian journal of gastroenterology
  98. Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study.2021Technology in cancer research & treatmentFree full text
  99. Identification of Key Genes for Hepatitis Delta Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis.2021The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  100. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.2021Transplant immunology
  101. Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Applications and challenges of pathomics technique in the management of hepatocellular carcinoma].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status15
  1. NK521 in the Treatment of Advanced Solid TumorsNot yet recruitingNCT07657416Study siteEarly phase 1Start 2027-01
  2. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  4. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  5. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  6. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  7. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  8. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  9. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  10. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  11. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  12. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  13. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  14. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  15. Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Study sitePhase 2Start 2010-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 84 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.9%.

Papers led
84
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 161620212022: 121220222023: 222220232024: 131320242025: 19192025

4 hospitals in Hefei for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AISurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led84
  1. Mechanism of triptolide in the treatment of gastric cancer with diabetes through JAK2/STAT3 pathway.2026European journal of pharmacology
  2. Ephrin‑B2 promotes gastric cancer growth by inhibiting apoptosis and regulating the cell cycle via the Wnt/β‑catenin signaling pathway.2026International journal of oncologyFree full text
  3. Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review.2025Biological researchFree full text
  4. RORα inhibits proliferation and chemoresistance through AKR1A1-induced glucose and lipid reprogramming in gastric cancer.2025Cellular signalling
  5. The Solute Carrier Family 47 Member 1, Transcriptionally Regulated by GATA Binding Protein 6, Inhibits Ferroptosis in Gastric Cancer.2025DNA and cell biology
  6. The role of CSTF2 in gastric cancer: implications for therapy.2025European journal of medical researchFree full text
  7. HEG1 promotes gastric cancer progression by stabilizing AKT1 and is functionally regulated by the deubiquitinase USP48.2025European journal of medical researchFree full text
  8. Investigating the relationship between tongue diagnosis features and gastric cancer: A machine learning-based prediction model.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Construction of nomogram prognostic model for gastric signet ring cell carcinoma: Signet ring cell proportion influencing prognosis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. ELAVL1 facilitates gastric cancer progression and metastasis through TL1A mRNA stabilization.2025Experimental cell research
  11. Identification of an M1 Macrophages-Related Signature for Predicting the Survival and Therapeutic Response in Gastric Cancer.2025IET systems biologyFree full text
  12. Nomogram for predicting primary resistance to anti-PD-1 therapy in advanced gastric cancer based on dynamic inflammatory markers: a multicenter retrospective study.2025International immunopharmacology
  13. Timing of Adjuvant Chemotherapy After Gastrectomy in Patients With Stage II to III Gastric Cancer: A Target Trial Emulation Study.2025JCO precision oncology
  14. NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism.2025Molecular medicine (Cambridge, Mass.)Free full text
  15. Complex intervention based on protective factors to improve resilience for gastric cancer patients: Mixed-methods process evaluation protocol.2025PloS oneFree full text
  16. A prognostic risk prediction model for gastric cancer based on the EFNA4 and ETS1 regulatory axis in tumor cells.2025Scientific reportsFree full text
  17. Integrin β5 interacts with G3BP1 through activating FAK/Src signaling pathway to promote gastric carcinogenesis.2025Scientific reportsFree full text
  18. Muscle-Driven prognostication in gastric cancer: A multicenter deep learning framework integrating Iliopsoas and erector spinae radiomics for 5-Year survival prediction.2025Scientific reportsFree full text
  19. Alcohol dehydrogenase iron containing 1 (ADHFE1) is associated with liver metastasis and regulates cellular function of gastric cancer.2025The International journal of biological markers
  20. Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer.2025World journal of gastroenterologyFree full text
  21. The PVT1-214/miR-671-5p/SLC45A4 signaling axis regulates cell proliferation in human gastric cancer.2025World journal of surgical oncologyFree full text
  22. UBR1 is a prognostic biomarker and therapeutic target associated with immune cell infiltration in gastric cancer.2024AgingFree full text
  23. SLAMF8 can predict prognosis of pan-cancer and the immunotherapy response effectivity of gastric cancer.2024Aging
  24. Identification of BANF1 as a novel prognostic biomarker in gastric cancer and validation via in-vitro and in-vivo experiments.2024AgingFree full text
  25. LncRNA UCA1 promotes vasculogenic mimicry by targeting miR-1-3p in gastric cancer.2024Carcinogenesis
  26. Pan-cancer analysis of TMEM45A and exploration of its prognostic value and mechanism in gastric cancer.2024Cellular and molecular biology (Noisy-le-Grand, France)
  27. Helicobacter pylori promotes gastric cancer progression by activating the TGF-β/Smad2/EMT pathway through HKDC1.2024Cellular and molecular life sciences : CMLSFree full text
  28. miR-135b-5p promotes gastric carcinogenesis by targeting CLIP4-mediated JAK2/STAT3 signal pathway.2024Cellular signalling
  29. GRWD1 Over-Expression Promotes Gastric Cancer Progression by Activating Notch Signaling Pathway via Up-Regulation of ADAM17.2024Digestive diseases and sciences
  30. Integrated single-cell RNA sequencing reveals the tumor heterogeneity and microenvironment landscape during liver metastasis in adenocarcinoma of esophagogastric junction.2024Frontiers in immunologyFree full text
  31. BNIP3 and DAPK1 methylation in peripheral blood leucocytes are noninvasive biomarkers for gastric cancer.2024Gene
  32. NFS1 inhibits ferroptosis in gastric cancer by regulating the STAT3 pathway.2024Journal of bioenergetics and biomembranes
  33. Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway.2024Journal of cancer research and clinical oncologyFree full text
  34. Exploring the Influence of T Cell Marker Gene Expression on the Pathobiology and Clinical Prognostic Outcomes in Intestinal-Type Gastric Carcinoma.2024Journal of gastrointestinal cancer
  35. Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy.2023BMC cardiovascular disordersFree full text
  36. Risk of lymph node metastasis and feasibility of endoscopic submucosal dissection in undifferentiated-type early gastric cancer.2023BMC gastroenterologyFree full text
  37. Comprehensive analysis of the biological function and immune infiltration of SLC38A2 in gastric cancer.2023BMC gastroenterologyFree full text
  38. Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.2023Cancer gene therapy
  39. Incorporation of liver chemistry score in predicting survival of liver-involved advanced gastric cancer patients who received palliative chemotherapy.2023Cancer medicineFree full text
  40. Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer.2023Cell cycle (Georgetown, Tex.)Free full text
  41. Lysine-specific Demethylase 6A Upregulates Cadherin-1 and Accelerates Gastric Cancer Growth.2023Current pharmaceutical biotechnology
  42. Prognostic value of tumor deposits in lymph node-negative gastric cancer: A propensity score matching study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  43. Incidence and mortality trends in gastric cancer in the United States, 1992-2019.2023International journal of cancer
  44. Prognostic significance of post-preoperative tumor markers increments in patients with non-metastatic gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  45. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  46. Comparison of different risk stratifications for gastric cancer and establishing a simplified risk-scoring model based on the Kyoto classification.2023Journal of gastroenterology and hepatology
  47. Prediction of overall survival after radical gastrectomy using nomograms created by tumor markers.2023Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  48. Oral microbiota disorder in GC patients revealed by 2b-RAD-M.2023Journal of translational medicineFree full text
  49. Demethylase FTO enhances the PI3K/Akt signaling to promote gastric cancer malignancy.2023Medical oncology (Northwood, London, England)
  50. Downregulated KDM6A mediates gastric carcinogenesis via Wnt/β-catenin signaling pathway mediated epithelial-to-mesenchymal transition.2023Pathology, research and practice
  51. PGAM5 promotes tumorigenesis of gastric cancer cells through PI3K/AKT pathway.2023Pathology, research and practice
  52. Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer.2023Redox biologyFree full text
  53. Efficacy and safety of esophageal submucosal tumors treated with internal traction method-assisted submucosal tunneling endoscopic resection: a single-center, single-blind, randomized controlled study.2023Surgical endoscopyRCT
  54. A Nomogram Based on the Log Odds of Positive Lymph Nodes Predicts the Prognosis of Patients with Colon Neuroendocrine Tumors After Surgery: A Surveillance, Epidemiology, and End Results Population-Based Study.2023Technology in cancer research & treatmentFree full text
  55. Tousled-like kinase 1 promotes gastric cancer progression by regulating the tumor growth factor-beta signaling pathway.2023World journal of gastroenterologyFree full text
  56. Comparison of the clinical and prognosis risk factors between endoscopic resection and radical gastrectomy for early-stage gastric cancer.2023World journal of surgical oncologyFree full text
  57. LncRNA CRYM-AS1 Inhibits Gastric Cancer Progression via Epigenetically Regulating CRYM.2022Annals of clinical and laboratory science
  58. Hyperglycemia induces miR-26-5p down-regulation to overexpress PFKFB3 and accelerate epithelial-mesenchymal transition in gastric cancer.2022BioengineeredFree full text
  59. SAMHD1, positively regulated by KLF4, suppresses the proliferation of gastric cancer cells through MAPK p38 signaling pathway.2022Cell cycle (Georgetown, Tex.)Free full text
  60. Combined Non-Invasive Prediction and New Biomarkers of Oral and Fecal Microbiota in Patients With Gastric and Colorectal Cancer.2022Frontiers in cellular and infection microbiologyFree full text
  61. A novel signature based on CeRNA and immune status predicts prognostic risk and drug sensitivity in gastric cancer patients.2022Frontiers in immunologyFree full text
  62. A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma.2022Frontiers in immunologyFree full text
  63. Icariin inhibits gastric cancer cell growth by regulating the hsa_circ_0003159/miR-223-3p/NLRP3 signaling axis.2022Human & experimental toxicology
  64. TIMP2 is associated with prognosis and immune infiltrates of gastric and colon cancer.2022International immunopharmacology
  65. A model established using marital status and other factors from the Surveillance, Epidemiology, and End Results database for early stage gastric cancer.2022Journal of investigative medicine : the official publication of the American Federation for Clinical ResearchFree full text
  66. circ_0044516 functions in the progression of gastric cancer by modulating MicroRNA-149-5p/HuR axis.2022Molecular and cellular biochemistry
  67. The Impact of a Simplified Scoring System on Long-Term Survival Outcomes in Patients with Gastric Cancer Undergoing Gastrectomy.2022Nutrition and cancer
  68. Prognostic significance of metastatic lymph node ratio in patients with gastric cancer after curative gastrectomy: a single-center retrospective study.2022Scandinavian journal of gastroenterology
  69. Circ_002059 suppresses cell proliferation and migration of gastric cancer via miR-182/MTSS1 axis.2021Acta biochimica et biophysica Sinica
  70. Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma.2021BMC cancerFree full text
  71. Prognostic value of different lymph node staging methods for node-positive cardia gastric cancer: a register-based retrospective cohort study.2021BMJ openRCTFree full text
  72. Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/miR-616-5p/DUSP2 axis.2021Basic & clinical pharmacology & toxicology
  73. Elevated expression of NFE2L3 promotes the development of gastric cancer through epithelial-mesenchymal transformation.2021BioengineeredFree full text
  74. Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  75. Peripheral Blood-Based DNA Methylation of Long Non-Coding RNA H19 and Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promoters are Potential Non-Invasive Biomarkers for Gastric Cancer Detection.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  76. Development and validation of a prognostic nomogram for gastric marginal zone lymphoma: a Surveillance, Epidemiology and End Results-based population study.2021Future oncology (London, England)
  77. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.2021International immunopharmacology
  78. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.2021Investigational new drugs
  79. Downregulating circRNA_0044516 Inhibits Cell Proliferation in Gastric Cancer Through miR-149/Wnt1/β-catenin Pathway.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  80. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.2021Journal of molecular medicine (Berlin, Germany)
  81. RORα and REV-ERBα are Associated With Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer.2021Technology in cancer research & treatmentFree full text
  82. Diagnostic Accuracy of Double Contrast-Enhanced Ultrasonography in Clarifying Tumor Depth (T Stage) of Gastric Cancer: Meta-analysis.2021Ultrasound in medicine & biology
  83. A novel method for π-shaped esophagojejunostomy and double-tract reconstruction (DTR) as an alternative in totally laparoscopic or robotic proximal gastrectomy for treating upper third proximal early gastric cancer.2021Updates in surgery
  84. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status19
  1. Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 ResectionStatus unknownNCT03817268Lead sponsorPhase 3Start 2019-01
  2. The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui ProvinceStatus unknownNCT03333967Lead sponsorStart 2017-09
  3. The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric CancerStatus unknownNCT01964027Lead (inferred)Phase 2Start 2013-10
  4. Diagnosis of Gastric Lesions From Exhaled Breath and SalivaCompletedNCT01420588Lead (inferred)Start 2011-08
  5. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  6. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East AsiaCompletedNCT05606094Study siteStart 2023-03
  7. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  8. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  9. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Study sitePhase 2Start 2021-08
  10. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  11. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Study sitePhase 3Start 2019-12
  12. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  13. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)CompletedNCT03399110Study sitePhase 3Start 2018-01
  14. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable FactorStatus unknownNCT03399253Study sitePhase 2/Phase 3Start 2017-12
  15. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  16. Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.WithdrawnNCT02736552Study sitePhase 3Start 2016-03
  17. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)CompletedNCT02745509Study siteN/AStart 2016-03
  18. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  19. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Hefei for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Expression of autophagy-related protein LC3B, p62, and cytoplasmic p53 in human retinoblastoma tissues.2016European review for medical and pharmacological sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 13 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 552025

10 hospitals in Hefei for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led13
  1. Dose-Dependent Ferroptosis Induction in Osteosarcoma via NRF2/GPX4 Axis Modulation by Plasma-Activated Liquid Therapy.2026Antioxidants & redox signaling
  2. CLEC5A suppresses cell growth and metastasis via interfering with the calcineurin/NFATc1 signaling pathway in osteosarcoma.2025Experimental cell research
  3. Prognostic and Therapeutic Significance of Cancer-Associated Fibroblasts Genes in Osteosarcoma Based on Bulk and Single-Cell RNA Sequencing Data.2025Journal of cellular and molecular medicine
  4. Tenascin-C-enriched extracellular vesicles contribute to osteosarcoma progression via regulation of the angiotensin II receptor type 1 pathway.2025Journal of molecular histology
  5. A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy.2025Journal of nanobiotechnology
  6. NEK2 promotes the progression of osteosarcoma through the AKT/p-AKT pathway and interacts with FoxM1.2025Medical oncology (Northwood, London, England)
  7. Controllable All-in-One Biomimetic Hollow Nanoscaffold Initiating Pyroptosis-Mediated Antiosteosarcoma Targeted Therapy and Bone Defect Repair.2024ACS applied materials & interfaces
  8. In situ hydrogel based on Cu-Fe3O4 nanoclusters exploits oxidative stress and the ferroptosis/cuproptosis pathway for chemodynamic therapy.2024Biomaterials
  9. VAMP8 suppresses the metastasis via DDX5/β-catenin signal pathway in osteosarcoma.2023Cancer biology & therapy
  10. Anti-Her2 affibody-decorated arsenene nanosheets induce ferroptosis through depleting intracellular GSH to overcome cisplatin resistance.2023Journal of nanobiotechnology
  11. Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy.2022Drug delivery
  12. A novel nomogram and risk classification system predicting the Ewing sarcoma: a population-based study.2022Scientific reports
  13. Cisplatin inhibits the proliferation of Saos-2 osteosarcoma cells via the miR-376c/TGFA pathway.2021Bosnian journal of basic medical sciences
Earlier papers (2016–2020)5
  1. Hsa_circ_0003732 promotes osteosarcoma cells proliferation via miR-545/CCNA2 axis.2020Bioscience reports
  2. Cold atmospheric plasma‑activated Ringer's solution inhibits the proliferation of osteosarcoma cells through the mitochondrial apoptosis pathway.2020Oncology reports
  3. Long noncoding RNA Breast cancer antiestrogen resistance 4 is associated with cancer progression and its significant prognostic value.2019Journal of cellular physiology
  4. A predictive model to estimate the pretest probability of metastasis in patients with osteosarcoma.2017Medicine
  5. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].2016Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Hefei for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Hefei for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Hefei for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 10 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.6%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 2220232024: 2220242025: 112025

5 hospitals in Hefei for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications
Departments in papersPathology / laboratory medicineRheumatology & immunology

Over half of these papers are lab or animal studies.

Papers it led10
  1. WTAP promotes the proliferation of multiple myeloma by regulating the hippo pathway through m6A modification of MAP6D1.2026Leukemia & lymphoma
  2. Dynamic monitoring of M-protein quantification by immunotyping using capillary zone electrophoresis during the chemotherapy of patients with multiple myeloma.2025Scientific reportsFree full text
  3. Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin.2024Laboratory medicine
  4. N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1.2024Molecular and cellular biochemistry
  5. Evolving roles of CD38 metabolism in solid tumour microenvironment.2023British journal of cancerFree full text
  6. Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature review.2023Immunity, inflammation and diseaseFree full text
  7. LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2.2022Cell biology and toxicology
  8. Acupuncture-exacerbated pyoderma gangrenosum associated with IgG multiple myeloma.2022Wounds : a compendium of clinical research and practice
  9. Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis.2021Leukemia research
  10. Long non‑coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR‑135b‑5p to target KLF9.2021Molecular medicine reports
All its trials on ClinicalTrials.gov, any status4
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  3. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10
  4. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 1 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Hefei for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 2 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 3.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Hefei for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led2
  1. Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac.2024Frontiers of medicine
  2. A case report of systemic lupus erythematosus presented as thrombotic thrombocytopenic purpura and successfully treated with plasmapheresis and belimumab.2022Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Hefei for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

2 hospitals in Hefei for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomyBiologic & complement drugsAntibodies & diagnosis
Departments in papersNeurologyRadiation oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 1 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Hefei for Wilson disease28 hospitals in China for Wilson disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07240896

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGenetics (ATP7B)Brain & movement symptoms
Departments in papersRadiology / nuclear medicine
Papers it led1
  1. Changes in brain susceptibility in Wilson's disease patients: a quantitative susceptibility mapping study.2024Clinical radiology
Chinese-language papers (not in the count)1
  1. [Research progresses in gene therapy for hepatolenticular degeneration].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)RecruitingNCT07240896Study siteEarly phase 1Start 2025-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 7 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 2.6%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 1120242025: 222025

2 hospitals in Hefei for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Hefei for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

5 hospitals in Hefei for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Hefei for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical phenotypes and genetic features of families with Duchenne muscular dystrophy].2020Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 11 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.5%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 1120242025: 332025

4 hospitals in Hefei for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePediatricsNephrology
Papers it led11
  1. POSTN promotes ferroptosis and contributes to the pathogenesis of IgA nephropathy via GPX4 downregulation.2025Acta histochemica
  2. Downregulation of CD36 alleviates IgA nephropathy by promoting autophagy and inhibiting extracellular matrix accumulation in mesangial cells.2025International immunopharmacology
  3. Protective effect of phosphoenolpyruvate carboxykinase 1 on inflammation and fibrotic progression of IgA nephropathy.2025Renal failure
  4. Causal role of immune cells in IgA nephropathy: a mendelian randomization study.2024Renal failure
  5. A novel clinical-radiomic nomogram for the crescent status in IgA nephropathy.2023Frontiers in endocrinology
  6. Renal histopathological manifestations of IgA vasculitis nephritis in children and adults.2023International immunopharmacology
  7. Development of a novel combined nomogram model integrating deep learning radiomics to diagnose IgA nephropathy clinically.2023Renal failureRCT
  8. Chemokine (C-C motif) receptor 2 is associated with the pathological grade and inflammatory response in IgAN children.2022BMC nephrology
  9. Noninvasive evaluation of IgA nephropathy fibrosis using Doppler ultrasound.2022Renal failure
  10. A Pooled Study of Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism in Relation to Risk, Pathology and Prognosis of Childhood Immunoglobulin A Vasculitis Nephritis.2021Biochemical genetics
  11. Enhanced Bruton's tyrosine kinase activity in the kidney of patients with IgA nephropathy.2021International urology and nephrology
Earlier papers (2016–2020)1
  1. IgG deposits in the mesangium and capillary loops predict poor renal outcome in patients with IgA nephropathy: a single-center retrospective study.2020Renal failure
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Hefei for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 3 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

3 hospitals in Hefei for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

4 hospitals in Hefei for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Hefei for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Bochdalek hernia.2018Lancet (London, England)

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Hefei for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 2 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

1 hospital in Hefei for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Hefei for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Hefei for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

安徽医科大学第一附属医院

First Affiliated Hospital of Anhui Medical University

合肥

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Affiliated Hospital of Anhui Medical University (AHMU); First affiliated Hospital of Anhui Medical University; P.R. China The First Affiliated Hospital of Anhui Medical University

Suggest a correctionDownload the data